ArticleFrontiers in immunology2026
Repulsive guidance molecule-a regulates neutrophil-associated Th17 responses in CNS autoimmunity.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and aim: Repulsive guidance molecule-A (RGMa) is well-known for its roles in T-cell-mediated neuroinflammation and CNS repair. Innate-adaptive immune interactions, particularly between neutrophils and Th17 cells, are emerging as critical drivers of neuroinflammatory pathology in multiple sclerosis (MS). Whether RGMa regulates these neutrophil-associated Th17 responses remains largely unknown. Elucidating this mechanism may reveal novel therapeutic targets for MS. Methods: Serum levels of RGMa, BMP4, neutrophil elastase (NE), IL-17A, and inflammatory markers were measured in 10 relapsing-remitting MS patients during acute relapse and remission phases, and in 10 healthy controls. Results: Serum RGMa and NE were elevated in acute-phase MS patients versus both remission and healthy controls ( Conclusion: RGMa contributes to neutrophil-associated Th17 inflammatory responses in CNS autoimmunity, potentially in association with BMP4-SMAD signaling. Targeting RGMa may therefore represent a potential therapeutic strategy for MS-associated neuroinflammation that warrants further investigation.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.